Latest News and Events
Filter by
Selections
September 23, 2024
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
Read MoreSeptember 10, 2024
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran
Read MoreSeptember 2, 2024
Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
Read MoreAugust 21, 2024
Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
Read MoreAugust 14, 2024
Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies
Read MoreAugust 8, 2024
Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street
Read MoreJuly 29, 2024